KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Biolife Solutions (BLFS) over the last 16 years, with Q3 2025 value amounting to $1.6 million.

  • Biolife Solutions' Change in Accured Expenses rose 48796.99% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 6778.85%. This contributed to the annual value of $6.5 million for FY2024, which is 22392.61% up from last year.
  • Latest data reveals that Biolife Solutions reported Change in Accured Expenses of $1.6 million as of Q3 2025, which was up 48796.99% from $864000.0 recorded in Q2 2025.
  • Biolife Solutions' 5-year Change in Accured Expenses high stood at $7.1 million for Q4 2024, and its period low was -$4.3 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $266000.0 (2024), whereas its average is $237578.9.
  • As far as peak fluctuations go, Biolife Solutions' Change in Accured Expenses tumbled by 354615.38% in 2021, and later soared by 86053.64% in 2024.
  • Biolife Solutions' Change in Accured Expenses (Quarter) stood at -$1.4 million in 2021, then soared by 195.52% to $1.3 million in 2022, then surged by 175.06% to $3.7 million in 2023, then surged by 91.09% to $7.1 million in 2024, then plummeted by 77.84% to $1.6 million in 2025.
  • Its Change in Accured Expenses was $1.6 million in Q3 2025, compared to $864000.0 in Q2 2025 and -$4.3 million in Q1 2025.